CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production

CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production

Chimeric antigen receptor (CAR)-T cells are engineered to identify and eliminate cells expressing a target antigen. Current manufacturing protocols vary between commercial CAR-T cell products warranting an assessment of these methods to determine which approach optimally balances successful manufact...

Full description

Bibliographic Details
Main Authors:	Julieta Abraham-Miranda, Meghan Menges, Reginald Atkins, Mike Mattie, Justyna Kanska, Joel Turner, Melanie J. Hidalgo-Vargas, Frederick L. Locke
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Immunology
Subjects:	chimeric antigen receptor T-cell CAR-T cell PBMC cryopreservation CAR-T cell in vitro expansion CAR-T cell cytokines production
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1007042/full

Similar Items

Impact of cryopreservation on CAR T production and clinical response
by: Karin Brezinger-Dayan, et al.
Published: (2022-10-01)

CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
by: Ler Yie Chan, et al.
Published: (2022-03-01)

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
by: Katharina Eva Ruppel, et al.
Published: (2022-03-01)

The role of MSCs and CAR-MSCs in cellular immunotherapy
by: Lun Yan, et al.
Published: (2023-08-01)

Approved CAR-T therapies have reproducible efficacy and safety in clinical practice
by: Daniel Goyco Vera, et al.
Published: (2024-12-01)

Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
by: Alejandrina Hernández-López, et al.
Published: (2025-01-01)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
by: Ali Keshavarz, et al.
Published: (2022-09-01)

The prognostic utility of 18F-FDG PET parameters in lymphoma patients under CAR-T-cell therapy: a systematic review and meta-analysis
by: Akram Al-Ibraheem, et al.
Published: (2024-09-01)

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
by: Zeljko Todorovic, et al.
Published: (2022-05-01)

Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors
by: Farhana Jahan, et al.
Published: (2023-02-01)

Charting new paradigms for CAR-T cell therapy beyond current Achilles heels
by: Ying Li, et al.
Published: (2024-05-01)

Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification
by: Jing Hu, et al.
Published: (2024-08-01)

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review
by: Vahid Moradi, et al.
Published: (2024-06-01)

Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic
by: Sergei Smirnov, et al.
Published: (2024-02-01)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
by: Alexandra Dreyzin, et al.
Published: (2023-03-01)

From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma
by: Jin Zhao, et al.
Published: (2024-05-01)

Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights
by: Zuhui Pu, et al.
Published: (2023-11-01)

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
by: Michael Hiltensperger, et al.
Published: (2023-03-01)

Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
by: Silvia Arcangeli, et al.
Published: (2020-06-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing
by: Gianna M. Branella, et al.
Published: (2021-12-01)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
by: Faezeh Ramezani, et al.
Published: (2023-11-01)

The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better
by: Rui Mao, et al.
Published: (2022-10-01)

CAR-based cell therapy: evaluation with bibliometrics and patent analysis
by: Yajun Yuan, et al.
Published: (2021-11-01)

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
by: Yuanyuan Yang, et al.
Published: (2024-11-01)

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
by: Tong Yu, et al.
Published: (2025-02-01)

Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer
by: Ivana Kutle, et al.
Published: (2024-12-01)

Corrigendum: Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer
by: Ivana Kutle, et al.
Published: (2025-02-01)

CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis
by: Cody D. Moorman, et al.
Published: (2023-10-01)

Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer
by: Carlos Moreno, et al.
Published: (2022-06-01)

Analysis of causes for poor persistence of CAR-T cell therapy in vivo
by: Yingjie Kong, et al.
Published: (2023-01-01)

CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
by: Hiu Kwan Carolyn Tang, et al.
Published: (2023-06-01)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
by: Hejin Jia, et al.
Published: (2019-06-01)

In silico and in vivo analysis reveal impact of c-Myc tag in FMC63 scFv-CD19 protein interface and CAR-T cell efficacy
by: Ana Julia Ferreira Lima, et al.
Published: (2024-12-01)

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers
by: Manuel Gotti, et al.
Published: (2020-10-01)

Application of novel CAR technologies to improve treatment of autoimmune disease
by: Abigail Cheever, et al.
Published: (2024-10-01)

How CAR T Cells Breathe
by: Christopher Forcados, et al.
Published: (2022-04-01)

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
by: Swati Garg, et al.
Published: (2023-11-01)

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
by: Piotr Celichowski, et al.
Published: (2023-03-01)

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies
by: Antonio Maria Alviano, et al.
Published: (2024-06-01)